Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations
NCT ID: NCT01479699
Last Updated: 2011-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2011-06-30
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo capsule
Four placebo capsules containing safflower oil only
Olive leaf extract capsules
Four capsules taken at baseline each containing 4mg oleuropein
Olive leaf extract capsule
Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
Olive leaf extract capsules
Four capsules taken at baseline each containing 4mg oleuropein
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olive leaf extract capsules
Four capsules taken at baseline each containing 4mg oleuropein
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Individuals who are vegetarian, have dietary restrictions or on a weight reducing diet will not be recruited.
* Subjects who have been taking antibiotics in previous 3 months before study will not be included in the study
* Females who may be pregnant, or if of childbearing potential and are not using effective contraceptive precautions will be excluded.
* Blood pressure \> 150/90 mmHg
* Haemoglobin \< 125 g/l for male, \< 110 g/l for female
* Gamma GT (liver enzymes) \> 80 IU/l
* Cholesterol \> 6.5 mmol/l
* Had suffered a myocardial infarction or stroke in the previous 12 months
* On any lipid-modifying medication
* On any medication affecting blood clotting
* Individuals taking vitamin and/or fish oil supplements
19 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Comvita UK
UNKNOWN
University of Reading
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeremy Paul Edward Spencer
Professor of Biochemistry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeremy PE Spencer, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Reading
Ian Rowland, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Reading
Parveen Yaqoob, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Reading
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hugh Sinclair Unit of Human Nutrition, University of Reading
Reading, Berkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OLE study
Identifier Type: -
Identifier Source: org_study_id